Sell Bank of Americ...
Open Question
Whats up with BMY today?
Page 1 of 1
The outlook for Bristol-Myers Squibb (BMY) is for some steady growth. The
consensus of analysts is that earnings per share of $1.93 in the most recent
fiscal year will advance to $1.93 in the current year and then grow to $2.20
next year. With a return on equity of 25.8% and priced at only 10.6 times this
year’s estimated net income and 9.3 times next year’s predicted net, it
seems attractively prices, especially with a dividend yield of more than 6%.
TheStreet.com Ratings quantitative evaluation model assigns BMY a “reward
grade” of B-plus, a “risk grade” of C-minus and an “overall grade” of
B-minus, which equates with a “buy” recommendation.
Despite what some pundits are predicting, Big Pharma isn’t about to shrivel up
and die.
Rate Now:
Average Rating: 0.00 / 0
Page 1 of 1
